Inovelon (Rufinamide)

Rufinamide stabilises neuronal activity by prolonging the inactive state of voltage‑gated sodium channels, which reduces neuronal hyperexcitability and helps prevent the abnormal electrical discharges that cause seizures in Lennox‑Gastaut syndrome.

The dosage of Inovelon is individualized by the prescribing physician based on the patient’s age, weight, renal function, and response to therapy. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Safety data for rufinamide in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Inovelon.

To place an order, submit an enquiry on the Inovelon product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Rufinamide’s mechanism of prolonging sodium‑channel inactivation differs from many traditional antiepileptics that enhance GABA activity or block calcium channels. This unique profile can be advantageous for patients who have not responded adequately to other seizure medications, though individual response varies.

Inovelon should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Inovelon is taken orally, usually as a tablet, with or without food as directed by the prescribing clinician. The exact timing and frequency depend on the individualized dosing schedule set by the healthcare professional.

Serious adverse events may include severe skin reactions, suicidal thoughts or behaviours, hepatic dysfunction, blood dyscrasias, and cardiac QT‑interval prolongation. Patients should be monitored regularly, and any concerning symptoms should be reported to a healthcare provider immediately.

Inovelon is contraindicated in patients with known hypersensitivity to rufinamide or any of its excipients. Caution is advised for individuals with significant liver disease, uncontrolled cardiac arrhythmias, or those taking interacting medications that could markedly alter rufinamide levels.